Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lisa Hammond, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cunningham R, Murray A, Byrne JS, Hammond L, Barry M, Mehigan D, Sheehan S. Venous thromboembolism prophylaxis guideline compliance: a pilot study of augmented medication charts. Ir J Med Sci. 2015 Jun; 184(2):469-74. PMID: 25023126.
    Citations: 2     Fields:    Translation:Humans
  2. Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol. 2008 Oct; 62(5):911-9. PMID: 18301896.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  3. Rowinsky EK, Beeram M, Hammond LA, Schwartz G, De Bono J, Forouzesh B, Chu Q, Latz JE, Hong S, John W, Nguyen B. A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):532-9. PMID: 17255275.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  4. Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res. 2006 Dec 15; 12(24):7406-13. PMID: 17189413.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  5. Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 01; 12(17):5207-15. PMID: 16951240.
    Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
  6. Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin Cancer Res. 2006 Jun 15; 12(12):3782-91. PMID: 16778106.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  7. Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2007 Feb; 59(2):165-74. PMID: 16736151.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  8. Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart Hood J, Merritt J, Rowinsky EK, Takimoto C, Von Hoff D, Eckhardt SG. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol. 2006 May 01; 24(13):2052-8. PMID: 16648505.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  9. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006 Feb 01; 24(4):552-62. PMID: 16391300.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  10. Ricart AD, Hammond LA, Kuhn JG, Takimoto CH, Goetz A, Forouzesh B, Forero L, Ochoa-Bayona JL, Berg K, Tolcher AW, Rowinsky EK. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8728-36. PMID: 16361560.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  11. Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol. 2006 Feb; 17(2):313-21. PMID: 16322117.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  12. Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2005 Nov 01; 11(21):7807-16. PMID: 16278403.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  13. Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2005 Nov 01; 11(21):7825-33. PMID: 16278405.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  14. McDermott DF, Hersh E, Weber J, Stephenson J, Cunningham CC, Ebbinghaus S, Thompson J, O'Day S, Weitman S, Hammond L. ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: Phase II experience. J Clin Oncol. 2005 Jun; 23(16_suppl):7556. PMID: 27946014.
    Citations:    
  15. de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec; 15(12):1825-33. PMID: 15550589.
    Citations: 17     Fields:    Translation:HumansAnimalsCTClinical Trials
  16. de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15; 10(22):7555-65. PMID: 15569986.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  17. Calvo E, Tolcher AW, Hammond LA, Patnaik A, de Bono JS, Eiseman IA, Olson SC, Lenehan PF, McCreery H, Lorusso P, Rowinsky EK. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin Cancer Res. 2004 Nov 01; 10(21):7112-20. PMID: 15534081.
    Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
  18. Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res. 2004 Oct 01; 10(19):6512-21. PMID: 15475438.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  19. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47. PMID: 15310767.
    Citations: 227     Fields:    Translation:HumansCTClinical Trials
  20. Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res. 2004 Aug 01; 10(15):4913-21. PMID: 15297391.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  21. Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2004 Aug 01; 10(15):5048-57. PMID: 15297406.
    Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
  22. Hammond LA, Ruvuna F, Cunningham CC, Ebbinghaus S, Rubin E, Mita A, Hersh E, Eder JP, Weiss J, Rowinsky EK. Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3068. PMID: 28014771.
    Citations:    
  23. Ebbinghaus S, Hersh E, Cunningham CC, O'Day S, McDermott D, Stephenson J, Richards DA, Eckardt J, Haider OL, Hammond LA. Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7530. PMID: 28014930.
    Citations:    
  24. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):7083. PMID: 28016137.
    Citations:    
  25. Bonate P, Ebbinghaus S, Eder JP, Mita A, Rubin E, Cunningham CC, Rowinsky EK, Hersh E, Craig AR, Hammond LA. Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2082. PMID: 28015689.
    Citations:    
  26. Mita A, Lockhart AC, Chen TL, Bochinski K, Curtright J, Cooper W, Hammond L, Rothenberg M, Rowinsky E, Sharma S. A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2025. PMID: 28015580.
    Citations:    
  27. Weiss GR, Mita A, Garrison M, Chu SQ, Syed S, Haider O, Bonate P, Hammond LA, Rowinsky EK. Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered iv weekly x 3 weeks every 4 weeks (wx3q4w). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3073. PMID: 28014756.
    Citations:    
  28. Schwartz G, Chu QS, Hammond LA, Mita M, Curtright J, Versola MJ, Koch K, Pandite LN, Ho PT, Rowinsky EK. Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3070. PMID: 28014766.
    Citations:    
  29. Hammond LA, Cavanaugh SX, Thomas CR. An image worth a thousand lives? Nat Biotechnol. 2004 Jun; 22(6):677-8. PMID: 15175685.
    Citations:    Fields:    Translation:HumansAnimalsCells
  30. Melendez RF, Harrison JM, Rowinsky EK, Hammond LA, Fitzsimmons TD. Acute retinal toxicity from the novel anti-tumor agent, Irofulven. Doc Ophthalmol. 2004 May; 108(3):249-51. PMID: 15573949.
    Citations:    Fields:    Translation:Humans
  31. Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res. 2004 Mar 01; 10(5):1645-56. PMID: 15014015.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  32. Hammond L, Street J, Downing J, Thompson J, Darke C. Immunogenetics of a new HLA-B null allele, HLA-B*4423N. Eur J Immunogenet. 2003 Dec; 30(6):385-6. PMID: 14675390.
    Citations:    Fields:    Translation:Humans
  33. Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies. Clin Cancer Res. 2003 Nov 15; 9(15):5540-9. PMID: 14654534.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  34. Patnaik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, Terada K, Gentner L, Rybak ME, Richards H, Zhang S, Rowinsky EK. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin Cancer Res. 2003 Oct 15; 9(13):4761-71. PMID: 14581347.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  35. Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2003 Sep 15; 9(11):4108-15. PMID: 14519633.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  36. Hammond LA. Pharmacokinetic evaluation of gefitinib when administered with chemotherapy. Clin Lung Cancer. 2003 Sep; 5 Suppl 1:S18-21. PMID: 14641990.
    Citations: 2     Fields:    Translation:Humans
  37. Hammond LA, Denis L, Salman U, Jerabek P, Thomas CR, Kuhn JG. Positron emission tomography (PET): expanding the horizons of oncology drug development. Invest New Drugs. 2003 Aug; 21(3):309-40. PMID: 14578681.
    Citations: 4     Fields:    Translation:HumansAnimals
  38. Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI, Hidalgo M. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res. 2003 Jul; 9(7):2478-86. PMID: 12855621.
    Citations: 14     Fields:    Translation:HumansCells
  39. Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, Rowinsky EK. A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. Clin Cancer Res. 2003 Jul; 9(7):2465-71. PMID: 12855619.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  40. Garrison MA, Hammond LA, Geyer CE, Schwartz G, Tolcher AW, Smetzer L, Figueroa JA, Ducharme M, Coyle J, Takimoto CH, De Jager RL, Rowinsky EK. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clin Cancer Res. 2003 Jul; 9(7):2527-37. PMID: 12855627.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  41. Schwartz GH, Patnaik A, Hammond LA, Rizzo J, Berg K, Von Hoff DD, Rowinsky EK. A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. Ann Oncol. 2003 May; 14(5):775-82. PMID: 12702533.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  42. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003 Apr 07; 88(7):1004-11. PMID: 12671695.
    Citations: 114     Fields:    Translation:HumansCells
  43. Street J, Hammond L, Downing J, Thompson J, Darke C. Observations on the HLA-A2403 specificity. Tissue Antigens. 2003 Apr; 61(4):330-3. PMID: 12753673.
    Citations:    Fields:    Translation:Humans
  44. Street J, Downing J, Hammond L, Thompson J, Darke C. Immunogenetics of two new HLA alleles: A*0108 and B*4031. Tissue Antigens. 2003 Apr; 61(4):322-4. PMID: 12753671.
    Citations:    Fields:    Translation:Humans
  45. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol. 2003 Jan 15; 21(2):211-22. PMID: 12525512.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  46. Rowinsky EK, Rizzo J, Ochoa L, Takimoto CH, Forouzesh B, Schwartz G, Hammond LA, Patnaik A, Kwiatek J, Goetz A, Denis L, McGuire J, Tolcher AW. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol. 2003 Jan 01; 21(1):148-57. PMID: 12506184.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  47. Darke C, Street J, Hammond L, Downing J, Thompson J. Immunogenetic study of a new HLA allele, B*2723. Tissue Antigens. 2002 Nov; 60(5):400-3. PMID: 12492816.
    Citations:    Fields:    Translation:HumansCells
  48. Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res. 2002 Jul; 8(7):2142-8. PMID: 12114414.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  49. Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Clin Cancer Res. 2002 Jul; 8(7):2157-66. PMID: 12114416.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  50. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002 May 01; 20(9):2240-50. PMID: 11980995.
    Citations: 130     Fields:    Translation:HumansCTClinical Trials
  51. de Bono JS, Stephenson J, Baker SD, Hidalgo M, Patnaik A, Hammond LA, Weiss G, Goetz A, Siu L, Simmons C, Jolivet J, Rowinsky EK. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol. 2002 Jan 01; 20(1):96-109. PMID: 11773159.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  52. Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol. 2001 Nov; 12(11):1631-41. PMID: 11822765.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  53. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001 Jul 01; 19(13):3267-79. PMID: 11432895.
    Citations: 199     Fields:    Translation:HumansCTClinical Trials
  54. Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Rowinsky EK. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol. 2001 Jun 01; 19(11):2937-47. PMID: 11387367.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  55. Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen DS, Skillings J, Rowinsky EK. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol. 2001 May 01; 19(9):2493-503. PMID: 11331328.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  56. Hammond LA, Davidson K, Lawrence R, Camden JB, Von Hoff DD, Weitman S, Izbicka E. Exploring the mechanisms of action of FB642 at the cellular level. J Cancer Res Clin Oncol. 2001 May; 127(5):301-13. PMID: 11355145.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  57. Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol. 2000 Dec 15; 18(24):4086-97. PMID: 11118470.
    Citations: 8     Fields:    Translation:Humans
  58. Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer. 2000 Dec; 36(18):2430-6. PMID: 11094320.
    Citations: 5     Fields:    Translation:HumansAnimals
  59. Patnaik A, Rowinsky EK, Tammara BK, Hidalgo M, Drengler RL, Garner AM, Siu LL, Hammond LA, Felton SA, Mallikaarjun S, Von Hoff DD, Eckhardt SG. Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. J Clin Oncol. 2000 Dec 01; 18(23):3974-85. PMID: 11099327.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  60. Rowinsky EK, Johnson TR, Geyer CE, Hammond LA, Eckhardt SG, Drengler R, Smetzer L, Coyle J, Rizzo J, Schwartz G, Tolcher A, Von Hoff DD, De Jager RL. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol. 2000 Sep; 18(17):3151-63. PMID: 10963644.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  61. Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O'Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol. 2000 Jan; 18(1):167-77. PMID: 10623707.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  62. Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, Morrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol. 2000 Jan; 18(1):178-86. PMID: 10623708.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  63. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol. 1999 Aug; 17(8):2604-13. PMID: 10561328.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  64. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res. 1999 Jul; 5(7):1629-37. PMID: 10430061.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  65. Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, Kuhn JG, Villalona-Calero MA, Hammond L, Weiss G, Thurman A, Smith L, Drengler R, Eckardt JR, Moczygemba J, Hannah AL, Von Hoff DD, Rowinsky EK. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol. 1999 Apr; 17(4):1095-104. PMID: 10561166.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  66. Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol. 1999 Feb; 17(2):685-96. PMID: 10080615.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  67. Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA, Eckhardt SG, Weiss GR, Rodriguez GI, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky EK. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. Clin Cancer Res. 1999 Feb; 5(2):299-308. PMID: 10037178.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  68. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J, Harding MW, Von Hoff DD. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998 Sep; 16(9):2964-76. PMID: 9738565.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  69. Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. J Clin Oncol. 1998 Aug; 16(8):2770-9. PMID: 9704730.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  70. Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD. Alternative dosing schedules for irinotecan. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):68-71. PMID: 9726095.
    Citations: 2     Fields:    Translation:Humans
  71. Hammond LA, Eckardt JR, Ganapathi R, Burris HA, Rodriguez GA, Eckhardt SG, Rothenberg ML, Weiss GR, Kuhn JG, Hodges S, Von Hoff DD, Rowinsky EK. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res. 1998 Jun; 4(6):1459-67. PMID: 9626463.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  72. Villalona-Calero MA, Eckardt J, Burris H, Kraynak M, Fields-Jones S, Bazan C, Lancaster J, Hander T, Goldblum R, Hammond L, Bari A, Drengler R, Rothenberg M, Hadovsky G, Von Hoff DD. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol. 1998 Jan; 9(1):71-7. PMID: 9541686.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Hammond's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (304)
Explore
_
Co-Authors (4)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.